Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 2

Conditions

Multiple Myeloma 72Lymphoma, Follicular 22Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Mantle-Cell 12Lymphoma 10Recurrence 8Neoplasms, Plasma Cell 8Lymphoma, B-Cell, Marginal Zone 8Lymphoma, Non-Hodgkin 7Leukemia, Lymphocytic, Chronic, B-Cell 7Smoldering Multiple Myeloma 4Neoplasms 3Neuroblastoma 2Neoplasm, Residual 2Myelodysplastic Syndromes 2Leukemia, Plasma Cell 2Leukemia, Myelomonocytic, Chronic 2Hodgkin Disease 2Hematologic Diseases 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Malignant Plasma Cell Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

Azacitidine 12Cyclophosphamide 10venetoclax 8fludarabine phosphate 7fludarabine 7Whole-Body Irradiation 7Biopsy 7Specimen Handling 6Mycophenolic Acid 6Injections 6Decitabine 6Tacrolimus 5Cytarabine 5Busulfan 5decitabine and cedazuridine drug combination 4Stem Cell Transplantation 4Peripheral Blood Stem Cell Transplantation 4Cyclosporine 4cedazuridine 3X-Rays 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3olutasidenib 2Vorinostat 2Sirolimus 2Rituximab 2Melphalan 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Idarubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × Lenalidomide × 90 days × Clear all
NCT00843882 2026-05-29

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
247 enrolled 19 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡